Related to IP-K Extends Collaborations with Sanofi-Aventis R&D and Novartis Tropical Disease Institute

• Sanofi-Aventis Shutters 13 Clinical Programs, Gains Four from Oxford BioMedica, and Returns TroVax
  
• Sanofi-Aventis Shells Out $65M to Antisoma for U.S. Rights to Leukemia Drug
  
• Novartis and Schering-Plough Divide Spoils of Respiratory Therapies Collaboration
  
• Sanofi-Aventis Pays $140M Up Front in Cancer Deal with Exelixis
  
• Novartis Offers 28% More for Increased Control over India Operations
  
• Novartis Vaccines Institute Gets Roughly $7M to Develop Bivalent Typhoid Vaccine
  
• Novartis and OneWorld Health Join Forces against Secretory Diarrhea
  
• Alnylam and Novartis Take RNAi Therapeutics Collaboration into Fifth Year
  
• Novartis Invests in Avila’s Protein-Silencing Covalent Drug Development Efforts
  
• Novartis Acquires Opexa’s Stem Cell Technology for $4M
  
• Novartis to Further Orexo’s Mid-Stage GERD Treatment
  
• BTG Sells Drug Delivery Platform to Novartis
  
• PerkinElmer Makes Two Acquisitions to Pad Diagnostics Business in Emerging Markets
  
• Sanofi-Aventis Gains License to Phase I Anticancer Agent from Merrimack for $60M Up Front
  
• Sandoz Launches Somatropin Biosimilar in Japan
  
• Novartis Nabs Global Commercialization Rights to Paratek's Late-Stage Antibiotic
  
• Novartis Shells Out $200M for U.S. and Canadian Rights to Vanda’s FDA-Approved Schizophrenia Drug
  
• Human Genome Sciences Earns $75M from Novartis as HCV Drug Gets Prepared for Regulatory Submissions
  
• Sanofi-Aventis Inks $350M Deal for Wellstat’s Phase II Therapy for Type 2 Diabetes
  

• Novartis to Exploit Nuevolution Platform for Drug Discovery